SHINE to supply n.c.a. Lu-177 for the clinical development of ImaginAb investigational radiopharmaceuticals
SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, and Telix Pharmaceuticals LTD (Telix), a biopharmaceutical company headquartered in Australia, today announced the signing of a clinical supply agreement that provides Telix with SHINE’s non-carrier-added (n.c.a.) lutetium-177 (Lu-177) for use in the clinical development of potential new therapeutics to treat prostate and kidney cancer.
SHINE Medical Technologies LLC today announced that they have entered into a distribution agreement enabling EDH to act as a SHINE-authorized distributor for selected countries